News articles about Pulmatrix (NASDAQ:PULM) have been trending positive recently, Accern Sentiment reports. The research firm rates the sentiment of news coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Pulmatrix earned a daily sentiment score of 0.26 on Accern’s scale. Accern also gave media stories about the biotechnology company an impact score of 47.0945521493162 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.
Shares of Pulmatrix (PULM) traded down 0.87% during midday trading on Friday, reaching $1.70. The company’s stock had a trading volume of 81,382 shares. The company has a 50 day moving average of $2.12 and a 200-day moving average of $2.89. Pulmatrix has a 52 week low of $0.50 and a 52 week high of $6.98. The stock’s market capitalization is $34.21 million.
Pulmatrix (NASDAQ:PULM) last posted its quarterly earnings data on Friday, August 4th. The biotechnology company reported ($0.29) EPS for the quarter, beating analysts’ consensus estimates of ($0.30) by $0.01. Pulmatrix had a negative net margin of 3,328.91% and a negative return on equity of 152.56%. Equities research analysts predict that Pulmatrix will post ($4.13) earnings per share for the current year.
TRADEMARK VIOLATION WARNING: This piece was reported by Community Financial News and is the sole property of of Community Financial News. If you are accessing this piece on another domain, it was stolen and reposted in violation of US and international copyright and trademark law. The original version of this piece can be accessed at https://www.com-unik.info/2017/08/19/favorable-news-coverage-somewhat-unlikely-to-affect-pulmatrix-pulm-stock-price-updated.html.
Pulmatrix, Inc is a clinical stage biopharmaceutical company developing inhaled therapies to address serious pulmonary disease. The Company’s product pipeline is focused on advancing treatments for rare diseases, including PUR1900, an inhaled anti-fungal for patients with lung disease, including cystic fibrosis.
What are top analysts saying about Pulmatrix Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Pulmatrix Inc. and related companies.